Bridgewest Group

What Bridgewest Group does

Bridgewest Group is a privately held global investment firm founded in 1999 by brothers Dr. Massih Tayebi and Dr. Masood Tayebi, headquartered in Coral Gables, Florida with a registered presence in San Diego. The firm manages over $3 billion in private capital across more than 70 portfolio companies operating in 60+ countries, organized into three core investment divisions — Private Equity (Life Sciences, Software, AI, Semiconductor), Venture Capital via Bridgewest Ventures (Deep Tech, MedTech, Life Science, Green Tech), and Real Estate — supported by Bridgewest Finance (non-bank private lending), the Bridgewest India Global Capability Center in Hyderabad, and a technology incubator in partnership with New Zealand's Callaghan Innovation.

The portfolio is anchored by a deep life sciences franchise: BioDuro-Sundia is described as the world's third-largest CRDMO with 10 global sites and 1,700+ employees; BioCina is a biologics CDMO operating the former Pfizer manufacturing facility in Adelaide and, following the 2025 BioCina/NovaCina merger, the Perth sterile injectable plant; BioAtla is a NASDAQ-listed oncology biotech built on the proprietary Conditionally Active Biologics (CAB) and CIAO! antibody optimization platforms (70+ patents); and BioOra is commercializing CAR-T cell therapies in partnership with Cincinnati Children's Hospital and Octane Biotech's Cocoon platform. On the technology side, Endura Technologies provides patented vertically integrated voltage regulator (VFIVR/eVR/sVR/eTC) power management silicon for AI compute and SoCs, with commercial partners MediaTek and UNISOC; Provoke Solutions and Pontis Technology (merged to form Ponteva) deliver enterprise software; TestMart applies AI-led ERP testing; and Projectworks sells project intelligence software.

Bridgewest's revenue mechanics combine private equity investment returns, venture capital fund management fees (Bridgewest Venture Fund I targeting NZ$100 million in commitments, NZ$60.2 million first close), private lending interest and transaction income (AU$5–30 million transactions in Australia, NZ$3 million–NZ$100 million loan portfolios in New Zealand), and operating income from real estate holdings. The firm's distinctive operating model — retaining nearly 100% of portfolio CEOs across exits, embedding operating partners and a captive GCC into portfolio companies, and holding assets without fund-mandated liquidation timelines — is the central pillar of its investment thesis and its primary competitive differentiator versus time-limited traditional PE and VC funds.

Name

Bridgewest Group

Legal name

Bridgewest Group, LLC

Website

http://bridgewestgroup.com/

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

Privately held global investment firm managing over $3B in capital across 70+ portfolio companies spanning life sciences, software, AI, semiconductors, and real estate. Founded in 1999 by the Tayebi brothers, it operates through private equity, venture capital, and direct lending.

Ownership category

akta.pro rank

Product category

Private Equity & Venture Capital Investment

NAICS

Portfolio Management and Investment Advice (52394), Credit Intermediation and Related Activities (522), Funds, Trusts, and Other Financial Vehicles (525)

SIC

Investment Advice (6282), Short-Term Business Credit Institutions (6153), Real Estate Agents & Managers (For Others) (6531)

akta.pro primary industry

Large-Cap / Sponsor Finance Direct Lending (FSANADAJ)

akta.pro secondary industries

CRE Bridge & Transitional Lending (FSALADAC), Convertible Notes / SAFE Bridge Lenders (FSANAIAJ)

Keywords

• Private equity investments
• Venture capital funding
• Life sciences investment
• Semiconductor technology investment
• Private lending services

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Private Equity Investment Returns: Bridgewest Group generates returns through controlling interest investments in high-growth technology companies. They provide capital infusion and operational expertise to portfolio companies, with nearly 100% of portfolio company CEOs staying on to form new ventures within Bridgewest after successful exits.
2. Venture Capital Fund Management: Bridgewest Ventures raises capital from institutional investors, family offices, high-net-worth individuals, and international migrant investors. They target deep-tech investments in Australia and New Zealand, targeting total commitments of NZ$100 million by Q4 2026.
3. Real Estate Holdings: The firm holds diverse real estate assets including commercial office, life science, and residential properties, as well as specialty facilities and hospitality properties globally.
4. Private Lending / Bridgewest Finance: Non-bank lending services offering flexible, tailored financing solutions to wholesale borrowers for residential and commercial developments. Operations established in New Zealand, United States, and Australia.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Bridgewest Group is a privately held global investment firm that makes controlling-interest investments in Life Sciences, Software, AI, and Semiconductor companies, providing capital infusion, operational mentorship, and global resources from idea inception through exit. The firm operates venture capital through Bridgewest Ventures for early-stage deep-tech investments in Australasia, private lending through Bridgewest Finance for wholesale borrowers, and holds a diversified real estate portfolio including commercial, life science, residential, specialty facilities, and hospitality assets.

Product overview

Bridgewest Group is a privately held global investment firm founded in 1999 with over $3B in private capital. The firm operates through three core investment divisions: Private Equity (Life Science, Software, AI, Semiconductor), Venture Capital (Bridgewest Ventures with Deep Tech VC, MedTech VC, Life Science VC, Green VC), and Real Estate. Supporting services include Bridgewest Finance (private lending), the Bridgewest India Global Capability Center, and a Technology Incubator program. The firm has invested in over 70 companies across 60+ countries, leveraging its eco-community of operating partners, subject matter experts, and global resources to guide entrepreneurs from idea inception through successful exits. Nearly 100% of portfolio company CEOs stay on to form new ventures within Bridgewest after exits. Key portfolio companies include BioDuro-Sundia (world's third largest CRDMO), BioCina (global CDMO), BioAtla (CAB cancer therapeutics), TestMart (AI-led ERP testing), Endura Technologies (semiconductor power management), Projectworks (project intelligence software), Provoke Solutions (software services), and multiple AI/MedTech/life sciences ventures.

Differentiator

Problem solved

Functional benefit

Brands

• BioDuro-Sundia: Contract research, development and manufacturing organization (CRDMO) - world's third largest
• BioCina
• BioAtla
• LumaCina
• Provoke Solutions
• Pontis Technology
• Endura Technologies
• Projectworks

Products and services

• Private Equity Investment
• Venture Capital (Bridgewest Ventures)
• Real Estate Investment

Quantifiable outcome

• BioAtla reached $1B+ market cap on NASDAQ in 2020
• +3 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Twelve partnerships are on record, tiered major, core and minor.

• Wellington Zhaotai Therapies LimitedmajorStrategic or Co-development Partner · 7 May 2026BioOra Limited and Wellington Zhaotai Therapies Limited (WZTL) signed Heads of Terms to advance their global expansion of CAR-T therapies.
• Cincinnati Children's Hospital Medical CentermajorStrategic or Co-development Partner · 13 April 2026BioOra and Cincinnati Children's Hospital Medical Center partnered to advance next-generation CAR-T therapy for children with leukemia.
• Octane BiotechcoreStrategic or Co-development Partner · 7 April 2026BioOra and Octane Biotech signed Letter of Intent to expand cell therapy manufacturing using the Cocoon platform.
• PwC CroatiacoreStrategic or Co-development Partner · 19 December 2024Strategic partnership between PwC Croatia and Pontis Technology to deliver innovative AI-powered solutions.
• Huadu InternationalcoreStrategic or Co-development Partner · 16 November 2023Strategic alliance between Huadu International and Bridgewest Ventures.
• Professor Carl JunecoreOthers · 30 October 2023BioOra appointed Professor Carl June, a pioneer in cell therapy, to its Board of Directors.
• Fisher & Paykel HealthcareminorChannel Partner/ Reseller/ Distributor · 22 April 2021Avasa recruited a senior commercial executive from Fisher & Paykel Healthcare to build its go-to-market strategy.
• Callaghan InnovationcoreStrategic or Co-development Partner · 13 January 2020Bridgewest Ventures was selected by Callaghan Innovation as one of four new partners to deliver its enhanced Technology Incubator programme in New Zealand. Bridgewest leverages its extensive international technology incubation experience and global resources to help local innovation-led ventures commercialize on a global scale.
• UNISOCmajorTechnology or Integration · 29 November 2018Commercial partnership to deliver power, performance, and area improvements in 12nm and 7nm advanced process nodes. Endura's eTC incorporated into next generation chipsets and sVR to improve performance and BOM costs of UNISOC products.
• PfizermajorStrategic or Co-development Partner · 19 March 2018Research collaboration with Pfizer Inc. led to the creation of AISF, a shelf-stable fluorosulfation reagent for synthesis of fluorosulfates and sulfamoyl fluorides, addressing challenges with sulfuryl fluoride gas.
• Porton Pharma SolutionscoreStrategic or Co-development Partner · 30 January 2018Cooperation agreement where BioDuro promotes and markets Porton's capabilities for pilot and large-scale GMP production of custom APIs and drug intermediates, while Porton incorporates BioDuro's drug discovery and formulation development services into their suite of solutions.
• MediaTekmajorTechnology or Integration · 4 May 2016Commercial partnership to demonstrate power, performance, and area improvements at advanced process nodes. Endura Technologies' eVR, sVR, and ATC solutions incorporated into MediaTek's latest product offerings at lowest process nodes.

Scale indicators12 records

Recent moves12 records

Expansion highlights7 records

Broad incumbents

• EQT Partners: Global investment organization with PE, venture, growth, and infrastructure strategies. Comparable to Bridgewest for the multi-strategy, multi-sector approach including healthcare and technology verticals.
• Clayton, Dubilier & Rice: Operating-partner-led private equity firm focused on large-cap complex transactions. Comparable to Bridgewest's hands-on operating partner approach and CEO-retention philosophy.
• CVC Capital Partners: Global private equity and credit manager with diversified sector exposure including healthcare and technology. Comparable to Bridgewest for diversified mid-to-large cap PE strategy.
• Cinven: European-led private equity firm investing across healthcare, technology, and business services. Comparable to Bridgewest for diversified PE strategy with strong healthcare/life sciences focus.
• 3i Group: UK-listed private equity and venture capital investor with diversified portfolio. Comparable to Bridgewest for the diversified PE/VC operating model and focus on long-hold operating businesses.
• Bridgepoint Group: European-based private equity firm with diversified mid-market investments across multiple sectors. Comparable to Bridgewest as a global PE investor with operating-partner philosophy and similar fund scale.
• H.I.G. Capital: Global mid-market private equity firm investing across sectors with operating value-add approach. Comparable to Bridgewest in fund size, multi-sector diversification, and hands-on operating partner model.
• Permira: Global investment firm with PE and credit strategies across technology, healthcare, and consumer. Comparable to Bridgewest given diversified sector exposure, life sciences focus, and significant AUM.

Direct peers

• Thoma Bravo: Software-focused private equity firm with concentrated portfolio of enterprise software companies. Comparable to Bridgewest's TestMart, Projectworks, Provoke, and Pontis software holdings and AI-led thesis.
• Hg (Hg Capital): Technology-focused private equity firm with deep operating expertise and large portfolio of software and tech-enabled businesses. Comparable to Bridgewest's software and AI vertical investing approach.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bridgewest-group/about

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bridgewest Group